2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1143

Periodontal Disease Is Associated with an Increased Risk of Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Abstract Number: 2432

Peripartum Issues in the Inflammatory Arthritis (IA) Patient: A Survey of the Rapport (Rheumatoid Arthritis Pharmacovigilence Program and Outcomes Research in New Therapies) Registry
Abstract Number: 2305

Peripheral Arterial Disease Is Associated with an Increased Risk of Subsequent Hip Fracture: A Systematic Review and Meta-Analysis of Cohort Studies
Abstract Number: 1082

Peripheral Blood CD11c+ CD21- Age-Associated B Cells (ABCs) in Human Systemic Lupus Erythematosus Are Associated with Innate Type III Interferon and Disease Activity
Abstract Number: 142

Peripheral CD4+CD25+Foxp3+T Regulatory Cells Absolutely Reduce in Patients with Systemic Lupus Erythematosus
Abstract Number: 2947

Peripheral Helper T Cells in Systemic Lupus Erythematosus
Abstract Number: 2732

Peripheral Neuropathy Is More Common in Microscopic Polyangiitis Than in Granulomatosis with Polyangiitis: Data from a Single Tertiary Referral Center
Abstract Number: 756

Peripheral Neutrophil CD64 Index Combined with Biomarkers Improves the Ability of Diagnosing Bacterial Infection in Patients with SLE
Abstract Number: 1236

Peripheral-Blood B-Cell Subset Disturbances in Whipple’s Disease
Abstract Number: 1209

Peritenon Extensor Tendon Inflammation, Synovitis and Enthesopathy in Psoriastic Arthritis: What Is the Connection?
Abstract Number: 548

Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Abstract Number: 1580

Persistent Serological Activity in Primary Sjögren’s Syndrome
Abstract Number: 2354

Perspectives of Patients with Inflammatory Arthritis Regarding Cardiovascular Risk: A Qualitative Study
Abstract Number: 1829

Perturbations of the Gut Fungal and Bacterial Microbiome with Biologic Therapy in Spondyloarthritis
Abstract Number: 1247

Pharmacist-Managed Titration of Urate-Lowering Therapy to Streamline Gout Management

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].